68 related articles for article (PubMed ID: 28383673)
21. Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Berenato R; Morano F; Pietrantonio F; Cotsoglou C; Caporale M; Infante G; Pellegrinelli A; Alessi A; Battiston C; Coppa J; Padovano B; Mennitto A; Niger M; Fucà G; Lazzati S; Greco G; Delconte G; de Braud F; Mazzaferro V; Di Bartolomeo M
Oncology; 2017; 93(5):279-286. PubMed ID: 28881354
[TBL] [Abstract][Full Text] [Related]
22. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
[TBL] [Abstract][Full Text] [Related]
23. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
Makris EA; MacBarb R; Harvey DJ; Poultsides GA
Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
[TBL] [Abstract][Full Text] [Related]
24. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
Chen Y; Yan H; Wang Y; Shi Y; Dai G
Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
[TBL] [Abstract][Full Text] [Related]
25. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
Chen S; Han L; Guo S; Tan Z; Dai G
Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
[TBL] [Abstract][Full Text] [Related]
26. Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects.
Yao W; Chen X; Fan B; Zeng L; Zhou Z; Mao Z; Shen Q
Front Oncol; 2023; 13():1077605. PubMed ID: 37007078
[TBL] [Abstract][Full Text] [Related]
27. Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Yu KH; Cockrum P; Surinach A; Lamarre N; Wang S; O'Reilly EM
Cancer Med; 2023 Apr; 12(8):9496-9505. PubMed ID: 36934451
[TBL] [Abstract][Full Text] [Related]
28. The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma.
Mohammed AA; Al-Zahrani O; Elsayed FM
Indian J Palliat Care; 2022; 28(4):406-412. PubMed ID: 36447500
[TBL] [Abstract][Full Text] [Related]
29. Survival prediction for patients with malignant biliary obstruction caused by pancreatic cancer undergoing biliary drainage: the COMBO-PaS model.
Zhou HF; Wang JL; Yang W; Zhou C; Shen Y; Wu LL; Pei ZL; Zhou WZ; Liu S; Shi HB
Surg Endosc; 2023 Mar; 37(3):1943-1955. PubMed ID: 36261643
[TBL] [Abstract][Full Text] [Related]
30. MM-associated circular RNA downregulates microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells.
Qian X; Zong W; Ma L; Yang Z; Chen W; Yan J; Xu J
Bioengineered; 2022 Apr; 13(4):9294-9300. PubMed ID: 35387554
[TBL] [Abstract][Full Text] [Related]
31. Cholangiocarcinoma: the quest for a second-line systemic treatment.
Vienot A; Neuzillet C
Transl Cancer Res; 2019 Apr; 8(Suppl 3):S275-S288. PubMed ID: 35117107
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging.
Rogers JE; Mizrahi JD; Nogueras Gonzalez GM; Surana R; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Raghav K; Pant S
J Gastrointest Oncol; 2021 Oct; 12(5):2268-2274. PubMed ID: 34790391
[TBL] [Abstract][Full Text] [Related]
33. The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study.
Jung HY; Lee EM
J Yeungnam Med Sci; 2022 Apr; 39(2):124-132. PubMed ID: 34663064
[TBL] [Abstract][Full Text] [Related]
34. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
35. Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models.
Cheng Q; Cai L; Zhang Y; Chen L; Hu Y; Sun C
Front Oncol; 2021; 11():639528. PubMed ID: 33747963
[No Abstract] [Full Text] [Related]
36. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.
de Jesus VHF; Camandaroba MPG; Calsavara VF; Riechelmann RP
Ther Adv Med Oncol; 2020; 12():1758835920905408. PubMed ID: 32165927
[TBL] [Abstract][Full Text] [Related]
38. Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy.
Blomstrand H; Adolfsson K; Sandström P; Björnsson B
Case Rep Gastrointest Med; 2020; 2020():4138215. PubMed ID: 32099693
[TBL] [Abstract][Full Text] [Related]
39. Estimating the decision curve and its precision from three study designs.
Pfeiffer RM; Gail MH
Biom J; 2020 May; 62(3):764-776. PubMed ID: 31394013
[TBL] [Abstract][Full Text] [Related]
40. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
